Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma

Chang, Victoria A.; Wang, Huan-You; Reid, Erin

doi:10.1182/bloodadvances.2018026351

Cited by 8 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Furthermore, several case reports have shown prolonged complete remission in patients. [42][43][44] In this study, only 2 of the 19 cases were PD-L1 positive on tumor cells and none PD-1 positive. With respect to immune cells of the environment, 3 samples tested positive for PD-L1 and 5 for PD-1.…”

Section: Discussionmentioning

confidence: 97%

A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients

Calvani

Gérard²,

Fadlallah³

et al. 2021

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Primary effusion lymphoma (PEL) is associated with human herpesvirus 8 and frequently with Epstein-Barr virus (EBV). We report here a single-center series of 19 human immunodeficiency virus-associated PELs, including 14 EBV + and 5 EBV − PELs. The objectives were to describe the clinicopathologic features of PELs, with a focus on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) expression, to search for genetic alterations by targeted deep sequencing analysis, and to compare the features between EBV + and EBV − cases. All the patients were male, and the median age at diagnosis was 47 years old (interquartile range: 40 to 56 y). Reflecting the terminal B-cell differentiation, immunophenotypic profiles showed low expression levels of B-cell markers, including CD19 (0/19), CD20 (1/19), CD79a (0/19), PAX5 (1/19), BOB1 (3/19), and OCT2 (4/19), contrasting with a common expression of CD38 (10/19), CD138 (7/19), and IRF4/MUM1 (18/19). We observed a frequent aberrant expression of T-cell markers, especially CD3 (10/19), and less frequently CD2 (2/19), CD4 (3/19), CD5 (1/19), and CD8 (0/19).Only 2 cases were PD-L1 positive on tumor cells and none PD-1 positive. With respect to immune cells, 3 samples tested positive for PD-L1 and 5 for PD-1. Our 36-gene lymphopanel revealed 7 distinct variants in 5/10 PELs, with either a single or 2 mutations per sample: B2M (n = 2), CD58 (n = 1), EP300 (n = 1), TNFAIP3 (n = 1), ARID1A (n = 1), and TP53 (n = 1). Finally, we did not observe any major clinical, pathologic, or immunohistochemical differences between EBV + and EBV − PELs and the outcome was similar (2-y overall survival probability of 61.

show abstract

Section: Discussionmentioning

confidence: 97%

A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients

Calvani

Gérard²,

Fadlallah³

et al. 2021

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…In one HIV-infected patient, a loss of CD30 expression was shown to be associated with a lack of BV efficacy. 53 All the other patients responded very well to this treatment, with a sustained CR achieved after 10, 16 and 39 months, respectively. [53][54][55] Moreover, CD30 can be used as a marker of persistent, transcriptionally active HIV-1-infected cells in the context of suppressive ART.…”

Section: T-cell Lymphomasmentioning

confidence: 80%

“…53 All the other patients responded very well to this treatment, with a sustained CR achieved after 10, 16 and 39 months, respectively. [53][54][55] Moreover, CD30 can be used as a marker of persistent, transcriptionally active HIV-1-infected cells in the context of suppressive ART. 56 There may be a secondary advantage to targeting CD30-positive cells in virologically suppressed HIV-related PEL.…”

Section: T-cell Lymphomasmentioning

confidence: 80%

CD30 as a therapeutic target in adult haematological malignancies: Where are we now?

et al. 2023

View full text Add to dashboard Cite

Summary CD30 is a transmembrane protein from the tumour necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms. CD30 is a particularly interesting treatment target because its levels are high in tumours but low in healthy tissues. Several therapeutic strategies targeting CD30 have been developed, including monoclonal antibodies, conjugated antibodies (combination of brentuximab vedotin with chemotherapy or immunotherapy), bispecific antibodies and cell and gene therapies, such as anti‐CD30 CAR‐T cells in particular. We briefly review the biology of CD30 which makes it a good therapeutic target, and we describe all of the anti‐CD30 therapies that have emerged to date.

show abstract

“…As PEL is usually CD30+, in preclinical data the use of brentuximab vedotin led to apoptosis of malignant cells and induced tumour regression and prolonged survival of mice with PEL [4] . There are a few case reports of HIV-related PEL treated with brentuximab vedotin with promising results after disease relapse [5] . In our case, we have presented a non-HIV patient with PEL who achieved complete remission with brentuximab vedotin, which highlights the potential role of a new therapeutic approach for non-HIV patients with PEL.…”

Section: Discussionmentioning

confidence: 99%

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma

Ferra

Mousinho

Miranda

et al. 2021

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

Primary effusion lymphoma is a rare and aggressive large B-cell lymphoma presenting as malignant effusion with poor prognosis. Although it is more prevalent among HIV patients, it has also been described in non-HIV immunocompromised individuals. Given its rarity, there are no large randomized trials regarding the best therapeutic option. The choice of therapy is based on retrospective studies, case reports and preclinical data. We present the case of a non-HIV patient with relapsed disease after treatment with CHOP who was then successfully treated with brentuximab vedotin, achieving complete remission.

show abstract

Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma

Abstract: Key Points Brentuximab vedotin is active in primary effusion lymphoma, a rare CD30-positive lymphoma with an extremely poor prognosis.

Cited by 8 publications

References 14 publications

A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients

A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients

CD30 as a therapeutic target in adult haematological malignancies: Where are we now?

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma

Contact Info

Product

Resources

About